Hemispherx Biopharma, Inc. Changes Name to AIM ImmunoTech Inc. Reflecting Ampligen’s® Immuno Modulation Progress in Ongoing Oncology Clinical Trials and ME/CFS

    NEXT STORY
    Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    PREV STORY
    Oasmia ADSs delisted from NASDAQ in the US
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    BeiGene to Present at the Deutsche Bank 43rd Annual Health Care Conference

    CAMBRIDGE, Mass., and BEIJING, China, May 04, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), ...

    author_avatar
    NASDAQ Market News

    Sanofi: EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma

      Press ReleaseSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) EMA to review cemiplimab as a ...

    author_avatar
    NASDAQ Market News

    Gateway Health to sponsor town hall meeting to address postpartum depression among Black women

    author_avatar
    NASDAQ Market News